Related Experiment Video
Updated: Jun 26, 2026
09:43
Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts
Published on: August 1, 2025
pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status
Asmaa Gaber Abdou1, Hayam Abdel Samie Aiad, Sultan Mohamed Sultan
1Department of Pathology, Faculty of Medicine, Menofiya University, Shebein Elkom, Egypt. Asmaa_elsaidy@yahoo.com
Summary
pS2 (TFF1) protein is highly expressed in prostate cancer, showing high diagnostic accuracy and sensitivity. Its nuclear pattern may indicate a favorable prognosis, distinct from estrogen receptor alpha.
Area of Science:
- Uro-oncology
- Molecular pathology
- Biomarker research
Background:
- pS2 (TFF1) is an estrogen-regulated protein found in the gastrointestinal tract.
- Its role in prostate lesions and correlation with steroid receptor status is poorly understood.
- pS2 is a potential indicator of estrogen receptor (ER) functionality.
Purpose of the Study:
- To correlate pS2 expression with steroid receptor status (ER alpha, PR) and pathological variables in prostate carcinoma.
- To evaluate the diagnostic value and prognostic implications of pS2 in prostate cancer.
Main Methods:
- Immunohistochemistry was used to assess pS2, ER alpha, and PR expression in 15 benign prostate hyperplasia (BPH) and 47 prostate carcinoma cases.
- Statistical analysis, including univariate survival analysis, was performed.
Main Results:
- pS2 was highly expressed in prostate carcinoma (91.4%) with both cytoplasmic and nuclear staining.
- Nuclear pS2 staining correlated significantly with lower Gleason scores (p=0.02).
- pS2 expression showed high diagnostic accuracy (74.19%), sensitivity (91.48%), and positive predictive value (78.18%).
Conclusions:
- pS2 is a sensitive marker for prostate carcinoma diagnosis, particularly in metastatic cases.
- pS2 expression is not significantly correlated with ER alpha or PR status, questioning ER alpha functionality in prostate.
- Nuclear pS2 patterns may identify prostate cancer patients with a favorable prognosis, potentially reflecting ER beta activity.